Cosmo Technologies secures FDA approval for Aemcolo to treat travelers’ diarrhea
Cosmo Technologies has achieved a significant milestone with the recent approval from the U.S. Food and Drug Administration (FDA) for its antibacterial drug, Aemcolo (rifamycin). This approval authorizes Aemcolo for the treatment of adult patients suffering from travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), provided the condition is not complicated by […]